Physician profile
Terry E Raposa
NPI 1174601744
$754.74
in general payments reported to CMS, 2019-2025
18 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.65 · 2024: $248 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155.48 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $105.61 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $88.92 | 2023-2025 | |
| Exact Sciences Corporation | $68.85 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $46.78 | 2024-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $36.15 | 2024-2025 | Airsupra |
| Alexion Pharmaceuticals, INC. | $35.92 | 2025 | Strensiq |
| Vertex Pharmaceuticals Incorporated | $33.58 | 2025 | |
| Baxter Healthcare | $29.91 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Hologic Sales and Service, LLC | $23.53 | 2024 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.83 | 2025 | Jardiance |
| Corcept Therapeutics | $18.22 | 2025 | Korlym |
| Organon LLC | $18.05 | 2025 | Nexplanon |
| Abbott Laboratories | $16.68 | 2025 | Id Now Instrument |
| Currax Pharmaceuticals LLC | $15.22 | 2025 | Contrave |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.22 | 2025 | |
| Amgen INC. | $14.13 | 2025 | Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.66 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Raposa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.